阿里拉姆制药 ALNY 深 沪
已收盘 12-19 16:00:00 美东时间
400.44
+4.400
+1.11%
华盛通- 最 高479.79
- 今 开399.11
- 成交量 167.32万股
- 最 低 387.03
- 昨 收 396.04
- 总市值 484.53亿
- 52周最高 495.55
- 市盈率 静 --
- 换手率 1.38%
- 52周最低 205.87
- 委 比 -82.38%
- 总股本 1.21亿
- 历史最高 495.55
- 量 比 1.32
- 振 幅 23.42%
- 历史最低 1.10
- 每 手 1
- 风险率 90.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alnylam Pharma To Invest $250M To Advance siRNA Enzymatic-Ligation Manufacturing Facility
New platform is expected to substantially increase manufacturing capacity and lower production costs, enabling investment in expanding pipelineFDA has accepted Alnylam's enzymatic ligation manufacturing platform into its
12-17 21:03
Health Canada Approves Alnylam's AMVUTTRA For ATTR Cardiomyopathy
Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with wild-type or
12-16 21:11
Is Alnylam Entering A Corrective Phase After A Strong Run?
A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.
12-16 20:04
Reported Friday, Nasdaq-100 Index Reconstituted As Alnylam, Ferrovial, Insmed, Monolithic Power, Seagate And Western Digital Join, While Biogen, CDW, GlobalFoundries, Lululemon, ON Semiconductor And Trade Desk Exit
As a result of the reconstitution, the following six companies will be removed from the Index: Biogen Inc. (NASDAQ:BIIB), CDW Corporation (NASDAQ:CDW), GlobalFoundries Inc. (NASDAQ:GFS), Lululemon Athletica Inc.
12-15 16:10
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday?
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome Powell th
10-31 01:40
BridgeBio(BBIO.US)指控辉瑞(PFE.US)、Alnylam(ALNY.US)在数十亿美元心脏病药市场采用“争议策略”竞争
BridgeBio Pharma(BBIO.US)正凭借一款心脏病药物与辉瑞(PFE.US)、Alnylam Pharmaceuticals(ALNY.US)展开竞争。该公司称其药物疗效更优且成本更低，但同时指控竞争对手在这个价值数十亿美元的市场中采用“有争议的策略”进行竞争。 争议焦点源于辉瑞本月在一场医学会议上播放的一段视频——视频中称其药物Vyndamax是治疗某类致命性心力衰竭的“首款且唯一获批疗法”，却刻意隐瞒了两项关键事实：BridgeBio的竞品药物已于2024年11月上市，而Alnylam的同类药物自今年3月起也已投入使用。BridgeBio首席执行官尼尔·库马尔(Neil K...
09-12 08:27
创新药狂飙90%，这轮袭榜选手的背后打法
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：聪明投资者 今年以来，创新药成为公募基金收益来源的关键“胜负手”...
07-22 15:03
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
EMPAVELI在Phase 3 VALIANT研究中对C3G和IC-MPGN患者显示蛋白质尿显著减少、肾功能稳定，且未见新安全信号。FDA和EMA正在审查上市申请。
06-06 13:15
美联储放“鸽”！纳指生物科技ETF(513290)放量涨超1%，美股创新药并购火热！阿斯利康豪掷10亿美元，进军CGT赛道
3月20日，纳指生物科技ETF（513290）盘中涨超1%，冲击三连涨，刷新近15个月以来新高！成交额超5700万元，环比放量！ 当地时间周三（3月1...
03-20 13:58
Demystifying Alnylam Pharmaceuticals: Insights From 15 Analyst Reviews
Analysts' ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) over the last quart...
03-12 02:00
